Novo Nordisk is currently investigating two amylin agonists, as well as oral [SC20] amycretin (NCT06049329 12 ) and subcutaneous amycretin (NCT06064006 13 ) a long-acting co-agonist of GLP-1 and amylin
Prescribers may consider dose adjustment strategies if bloating significantly impairs quality of life
WestHWSiddiqueMWilliamsMCVolpeLDesaiRLyashevaMet alDeep-learning for epicardial adipose tissue assessment with computed tomography: implications for cardiovascular risk prediction
While research is still emerging on the relationships between GLP-1 medications and birth control, fertility, and pregnancy, manufacturers of these popular weight-loss drugs have provided recommendations for women who are currently taking oral contraceptives to avoid pregnancy
This article examines the emerging evidence, proposed mechanisms involving brain reward pathways, and important safety considerations for clinicians and patients navigating this investigational area
Understanding GLP-1 Medications GLP-1 medications mimic the natural hormone GLP-1, which is produced in the gut in response to eating